Reply to: "Refutation of the αSyn-SAA-Based Staging for Parkinson's Progression (Neuronal α-Synuclein Disease-Integrated Staging System [NSD-ISS])".
作者信息
Simuni Tanya, Chahine Lana M, Poston Kathleen L, Kopil Catherine M, Weintraub Daniel, Dunn Billy, Marek Kenneth
机构信息
Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
出版信息
Mov Disord. 2025 Aug;40(8):1746-1747. doi: 10.1002/mds.30272. Epub 2025 Jun 27.
Abstract
摘要
相似文献
1
Reply to: "Refutation of the αSyn-SAA-Based Staging for Parkinson's Progression (Neuronal α-Synuclein Disease-Integrated Staging System [NSD-ISS])".回复：“对基于α突触核蛋白-血清淀粉样蛋白A的帕金森病进展分期的反驳（神经元α突触核蛋白病综合分期系统[NSD-ISS]）”
Mov Disord. 2025 Aug;40(8):1746-1747. doi: 10.1002/mds.30272. Epub 2025 Jun 27.
2
Refutation of the αSyn-SAA-Based Staging for Parkinson's Progression (Neuronal α-Synuclein Disease-Integrated Staging System [NSD-ISS]).对基于α突触核蛋白-血清淀粉样蛋白A的帕金森病进展分期（神经元α-突触核蛋白病综合分期系统[NSD-ISS]）的驳斥。
Mov Disord. 2025 Aug;40(8):1744-1745. doi: 10.1002/mds.30269. Epub 2025 Jun 27.
3
SynNeurGe: The road ahead for a biological definition of Parkinson's disease.SynNeurGe：帕金森病生物学定义的未来之路。
J Parkinsons Dis. 2024 Dec 8:1877718X241298194. doi: 10.1177/1877718X241298194.
4
Neuronal α-Synuclein Disease Stage Progression over 5 Years.神经元α-突触核蛋白疾病5年的阶段进展
Mov Disord. 2025 Apr 30. doi: 10.1002/mds.30191.
5
A perspective of persons with Parkinson's disease on the contribution of alpha-synuclein seed amplification assay biomarker to the diagnosis of Parkinson's disease.帕金森病患者对α-突触核蛋白种子扩增检测生物标志物在帕金森病诊断中作用的看法。
J Parkinsons Dis. 2025 Aug;15(5):953-956. doi: 10.1177/1877718X251315651. Epub 2025 Feb 6.
6
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.神经元α-突触核蛋白病的生物学定义：建立研究用综合分期系统。
Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2.
7
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts.神经元α-突触核蛋白病综合分期系统在PPMI、帕萨迪纳和SPARK基线队列中的表现。
NPJ Parkinsons Dis. 2024 Sep 27;10(1):178. doi: 10.1038/s41531-024-00789-w.
8
A minimally invasive biomarker for sensitive and accurate diagnosis of Parkinson's disease.一种微创生物标志物，用于敏感、准确地诊断帕金森病。
Acta Neuropathol Commun. 2024 Oct 22;12(1):167. doi: 10.1186/s40478-024-01873-1.
9
Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study.α-突触核蛋白种子扩增检测动力学指标在帕金森病中的诊断和预后价值：一项纵向队列研究
Lancet Neurol. 2025 Jul;24(7):580-590. doi: 10.1016/S1474-4422(25)00157-7.
10
A minimally Invasive Biomarker for Sensitive and Accurate Diagnosis of Parkinson's Disease.一种用于帕金森病灵敏且准确诊断的微创生物标志物。
medRxiv. 2024 Jun 30:2024.06.29.24309703. doi: 10.1101/2024.06.29.24309703.
引用本文的文献
1
Revisiting Parkinson's disease definition and classification: insights from two emerging biological frameworks.重新审视帕金森病的定义和分类：来自两个新兴生物学框架的见解。
J Neural Transm (Vienna). 2025 Sep 4. doi: 10.1007/s00702-025-03013-y.
本文引用的文献
1
Refutation of the αSyn-SAA-Based Staging for Parkinson's Progression (Neuronal α-Synuclein Disease-Integrated Staging System [NSD-ISS]).对基于α突触核蛋白-血清淀粉样蛋白A的帕金森病进展分期（神经元α-突触核蛋白病综合分期系统[NSD-ISS]）的驳斥。
Mov Disord. 2025 Aug;40(8):1744-1745. doi: 10.1002/mds.30269. Epub 2025 Jun 27.
2
Neuronal α-Synuclein Disease Stage Progression over 5 Years.神经元α-突触核蛋白疾病5年的阶段进展
Mov Disord. 2025 Apr 30. doi: 10.1002/mds.30191.
3
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders.神经退行性疾病临床药物研发中的生物标志物引导决策
Nat Rev Drug Discov. 2025 Apr 4. doi: 10.1038/s41573-025-01165-w.
4
Cognitive effects of Lewy body pathology in clinically unimpaired individuals.路易体病在临床无明显障碍个体中的认知影响。
Nat Med. 2023 Aug;29(8):1971-1978. doi: 10.1038/s41591-023-02450-0. Epub 2023 Jul 18.
Zotero 插件